Opinion/decision on a Paediatric investigation plan (PIP): Tofacitinib, decision type: , therapeutic area: , PIP number: P/0055/2017
Human medicines European public assessment report (EPAR): Harvoni, ledispavir,sofosbuvir, Hepatitis C, Chronic, Date of authorisation: 17/11/2014, Revision: 28, Status: Authorised
Human medicines European public assessment report (EPAR): Epclusa, sofosbuvir,velpatasvir, Hepatitis C, Chronic, Date of authorisation: 06/07/2016, Revision: 22, Status: Authorised
Opinion/decision on a Paediatric investigation plan (PIP): Brincidofovir, decision type: , therapeutic area: , PIP number: P/0180/2022
Human medicines European public assessment report (EPAR): Ultomiris, ravulizumab, Hemoglobinuria, Paroxysmal, Date of authorisation: 02/07/2019, Revision: 13, Status: Authorised
Quarterly system demo - Q3 2023, Online, 09:00 - 13:00 Amsterdam time (CEST), from 21/09/2023 to 21/09/2023
How to find us
Orientation guide for patient representatives and healthcare professionals - EMA building
Orientation guide for delegates - EMA building
Human medicines European public assessment report (EPAR): Abrysvo, Respiratory syncytial virus vaccine (bivalent, recombinant), Respiratory Syncytial Virus Infections, Date of authorisation: 23/08/2023, Status: Authorised